pharmaphorum

SEPTEMBER 21, 2021

Fortunately, we are now experiencing significant progress in gene therapy and other platform approaches targeting rare diseases, with a number of them focused on devastating CNS conditions. The post It’s time to do better for patients with rare neurological disorders appeared first on.

Gene Therapy 90

Gene Therapy Gene Clinical Trials Clinical Trials 90

pharmaphorum

AUGUST 8, 2022

CRISPR Therapeutics and Vertex are also in the running with their gene-editing candidate CTX001, in phase 1/2 trials which are due to generate final results later this year. billion takeover bid for Biohaven and its migraine therapy Nurtec ODT (rimegepant). It comes shortly after the group closed a $6.7

Marketing 111

Marketing Sales Gene Editing Antibody 111

pharmaphorum

JANUARY 13, 2023

Sanofi Ventures invests in innovators working in areas including immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science.

Gene Therapy 52

Gene Therapy Business Development Gene Vaccination 52

pharmaphorum

OCTOBER 12, 2022

and France to accelerate the development of genomic therapies. Genethon is one of the pioneers in gene therapy, and we’ve been helping them with machine learning to develop a new viral vector for metabolic diseases,” Del Bourgo says. “So Genethon, a French biotech, is one such collaborator.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

DECEMBER 16, 2022

Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Pete previously worked with Amazon, Babylon Health, and Sony. Other pharma supplier hires.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

The Pharma Data

OCTOBER 15, 2020

The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc.,

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

The Pharma Data

DECEMBER 17, 2020

SpringWorks Therapeutics — Badreddin Edris has been promoted from chief business officer to COO and Mary Smith, Mary Smith, currently senior vice president of Clinical Research and Development, has been promoted to chief development officer at SpringWorks. Rinri Therapeutics – Terri Gaskell was named CTO of U.K.-based

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

NOVEMBER 3, 2020

In addition, LogicBio has a collaboration with Takeda to research and develop LB-301, an investigational therapy leveraging GeneRide for the treatment of the rare pediatric disease Crigler-Najjar syndrome. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

XTalks

MAY 17, 2024

Prior to joining Calliditas Therapeutics as CMO, he held roles at GlaxoSmithKline (GSK) and Takeda, focusing on clinical and business development in rare diseases. I’ve had a great passion for drug development in rare diseases,” says Dr. Philipson, underscoring a commitment that would shape his career’s trajectory.

Development 52

Development Drugs Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Before joining Kite, he was chief scientific officer at Dutch AM-Pharma, Business Unit Manager at TNO Biosciences and chief executive officer at SomantiX.

Genome 40

Genome Genomics Medicine Life Science 40

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Meanwhile, BioMarin’s gene therapy Roctavian is approved by the FDA for the treatment of hemophilia A.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

JANUARY 26, 2023

Cell and gene therapies are predicted to be the future of medical treatment by providing the body with the means to repair itself and recover from a range of serious conditions and severe diseases. Often, cell and gene therapies are spoken of as miracle treatments, yet this progress has hardly occurred overnight.

Gene Therapy 130

Gene Therapy Gene Medicine Manufacturing 130

Pharmaceutical Technology

MARCH 20, 2023

Research – and money – going into even more advanced gene therapies is ramping up. Genomics is set to have a major impact on understanding, preventing, and treating a huge range of diseases; cell and gene therapies will bolster oncology investment, for example, with several such drugs currently in development.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225

Pharmaceutical Technology

MAY 9, 2023

The purchase of Viroclinics-DDL, an established global specialist virology and vaccine development contract research organisation, gives Cerba Research the opportunity to enhance solutions across therapeutic areas, explore new geographies and build best-in-class logistics services, while reducing risks for customers.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130

Drug Discovery World podcast

DECEMBER 5, 2024

They are called: “ Accelerating time to market through digitalisation ”, “ Why digital biomarkers will power tomorrow’s Alzheimer’s therapies ”, and “ The path to improved safety of gene-based products ”. The post The far-reaching impact of drug discovery technology appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Gene Therapy Gene Business Development 52